These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 13710931)

  • 1. [Fibrin, fibrinolysis and arterosclerosis].
    HALSE T
    Med Welt; 1960 Aug; 33-34():1662-8. PubMed ID: 13710931
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fibrinolysis incidence in arteriosclerosis-induced illnesses as well as in arteriosclerosis positive and negative syntropic diseases].
    Schulz FH; Bach G; Künzel A
    Dtsch Gesundheitsw; 1970 Apr; 25(15):682-4. PubMed ID: 5483709
    [No Abstract]   [Full Text] [Related]  

  • 3. [Data on the increase of non-protein nitrogen during coagulation & fibrinolysis in arteriosclerosis].
    JANIAKOWA A; KOTLAREK-HAUS S; POTOCZEK S; TKACZEWSKI W
    Pol Tyg Lek (Wars); 1958 Jun; 13(24):921-3. PubMed ID: 13578772
    [No Abstract]   [Full Text] [Related]  

  • 4. [From fibrinogen to fibrin and its dissolution].
    Juhan-Vague I; Hans M
    Bull Acad Natl Med; 2003; 187(1):69-82; discussion 83-4. PubMed ID: 14556455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Coagulolysis and fibrinolysis in atheromatosis].
    GIBINSKI K
    Pol Tyg Lek; 1961 May; 16():781-3. PubMed ID: 13705098
    [No Abstract]   [Full Text] [Related]  

  • 6. [Spontaneous fluctuations in fibrinolysis].
    Shershevskiĭ MG
    Lab Delo; 1966; 5():274-6. PubMed ID: 4168948
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancement of endogenous fibrinolysis does not reduce local fibrin deposition, but modulates inflammation upon intestinal ischemia and reperfusion.
    Schoots IG; Levi M; van Vliet AK; Declerck PJ; Maas AM; van Gulik TM
    Thromb Haemost; 2004 Mar; 91(3):497-505. PubMed ID: 14983225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.
    Ganguly K; Goel MS; Krasik T; Bdeir K; Diamond SL; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1130-6. PubMed ID: 16284278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Methods for evaluation of regional fibrinolysis. Studies made in atherosclerotic and thrombophlebitic disease].
    Tesi M; Pandolfi M
    Boll Soc Ital Cardiol; 1973; 18(6):524-46. PubMed ID: 4807083
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies of hemostatic equilibrium in senile and presenile thyropathies in relation to atherosclerotic disease].
    Perego MA; Isidori A; Vercelloni B
    Folia Endocrinol; 1967 Apr; 20(2):182-90. PubMed ID: 5630519
    [No Abstract]   [Full Text] [Related]  

  • 11. [On fibrinolysis in atherosclerosis].
    Sukhanov AA
    Klin Med (Mosk); 1968 May; 46(5):106-9. PubMed ID: 5669569
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inflammation, fibrin and fibrinolysis].
    Businco L
    Clin Eur; 1965; 4(6):423-5. PubMed ID: 5884395
    [No Abstract]   [Full Text] [Related]  

  • 13. Two families of synthetic peptides that enhance fibrin turbidity and delay fibrinolysis by different mechanisms.
    Pandi L; Kollman JM; Lopez-Lira F; Burrows JM; Riley M; Doolittle RF
    Biochemistry; 2009 Aug; 48(30):7201-8. PubMed ID: 19588915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The TAFI system. The new role of fibrinolysis].
    Dempfle CE
    Hamostaseologie; 2007 Sep; 27(4):278-81. PubMed ID: 17938767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis.
    Pannell R; Kung W; Gurewich V
    J Thromb Haemost; 2007 May; 5(5):1047-54. PubMed ID: 17459007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of gamma' fibrinogen splice variant on fibrin physical properties and fibrinolysis rate.
    Collet JP; Nagaswami C; Farrell DH; Montalescot G; Weisel JW
    Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):382-6. PubMed ID: 14656741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immobilization of aprotinin to fibrinogen as a novel method for controlling degradation of fibrin gels.
    Smith JD; Chen A; Ernst LA; Waggoner AS; Campbell PG
    Bioconjug Chem; 2007; 18(3):695-701. PubMed ID: 17432824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
    Gombás J; Tanka-Salamon A; Skopál J; Nagy Z; Machovich R; Kolev K
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):82-8. PubMed ID: 18180621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fibrinolytic activity of the plasma in atherosclerosis].
    RAYNAUD R; BROCHIER M; GRIGUER P
    Bull Mem Soc Med Hop Paris; 1961 May 12-19; 77():576-8. PubMed ID: 13739985
    [No Abstract]   [Full Text] [Related]  

  • 20. [Evaluation of the determination of fibrinolysis using an agarose fibrin plate].
    Kurotaki E; Odashima H; Sekikawa H; Ichinose Y; Miura Y
    Rinsho Byori; 1974 Oct; 22(10 Suppl):104. PubMed ID: 4475714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.